Skip to main content
. 2013 May 14;13:467. doi: 10.1186/1471-2458-13-467

Table 3.

Mean change at 6th months from baseline in clinical data

 
Intervention
Control
Model 1 (crude)
Model 2 (adjusted)
Model 3 (adjusted)
Model 4 (adjusted)
  Mean ± SE Mean ± SE Difference 95%CI p-value Difference 95%CI p-value Differences 95%CI p-value Difference 95%CI p-value
HbA1c(%)#
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−0.7
±
0.1
−0.2
±
0.1
−0.5
(−0.8 to −0.2)
0.004
−0.5
(−0.8 to −0.2)
0.004
−0.5
(−0.8 to −0.2)
0.003
−0.5
(−0.9 to −0.1)
0.011
CDS2)
−0.7
±
0.1
−0.2
±
0.1
−0.5
(−0.9 to −0.1)
0.009
−0.4
(−0.8 to −0.1)
0.014
−0.5
(−0.1 to −0.8)
0.013
−0.5
(−1.0 to −0.1)
0.028
MI3)
−0.7
±
0.1
−0.3
±
0.1
−0.5
(−0.9 to −0.1)
0.030
−0.4
(−0.8 to −0.1)
0.041
−0.4
(−0.8 to −0.2)
0.045
−0.4
(−0.6to −0.0)
0.045
BMI(kg/m2)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−0.5
±
0.1
−0.3
±
0.2
−0.2
(−0.7 to 0.2)
0.351
−0.1
(−0.6 to 0.4)
0.598
−0.1
(−0.6 to 0.3)
0.548
−0.3
(−0.8 to 0.2)
0.221
CDS2)
−0.6
±
0.2
−0.3
±
0.2
−0.3
(−0.8 to 0.1)
0.146
−0.2
(−0.8 to 0.3)
0.331
−0.3
(−0.8 to 0.3)
0.297
−0.3
(−0.9 to 0.2)
0.216
MI3)
−0.5
±
0.1
−0.3
±
0.2
−0.2
(−0.7 to 0.2)
0.351
−0.1
(−0.7 to 0.5)
0.693
−0.1
(−0.7 to 0.4)
0.633
−0.1
(−0.6 to 0.5)
0.829
FPG(mg/dl)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−19
±
8
−20
±
8
1
(−23 to 25)
0.919
8
(−11 to 28)
0.367
9
(−11 to 29)
0.347
22
(−10 to 54)
0.165
CDS2)
−20
±10
10
−14
±
11
7
(−37 to 23)
0.633
1
(−23 to 25)
0.933
0
(−25 to 25)
0.993
5
(−33 to 43)
0.792
MI3) $
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SBP(mmHg)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−1
±
3
0
±
3
1
(−9 to 7)
0.748
−1
(−7 to 6)
0.802
0
(−7 to 6)
0.963
0
(−8 to 8)
0.951
CDS2)
−1
±
3
−2
±
3
1
(−7 to 9)
0.804
2
(−5 to 9)
0.514
4
(−4 to 9)
0.416
4
(−5 to 12)
0.370
MI3)
−1
±
3
−2
±
3
−1
(−9 to 7)
0.738
−2
(−8 to 5)
0.593
−2
(−9 to 5)
0.523
−3
(−11 to 4)
0.368
DBP(mmHg)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−1
±
1
−3
±
2
1
(−3 to 6)
0.560
−3
(−1 to 7)
0.164
−2
(−2 to 6)
0.239
4
(−1 to 8)
0.088
CDS2)
−0
±
1
−4
±
1
3
(−1 to 7)
0.159
4
(−0 to 8)
0.050
4
(−0 to 8)
0.073
5
(0 to 10)
0.049
MI3)
−1
±
1
−3
±
2
−2
(−7 to 2)
0.296
−3
(−8 to 1)
0.120
−3
(−8 to 1)
0.166
−3
(−8 to 2)
0.171
LDL(mg/dl)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−5
±
2
−1
±
2
−4
(−10 to 3)
0.286
−2
( −8 to 3)
0.387
−3
(−10 to 3)
0.245
−4
(−13 to 5)
0.344
CDS2)
−4
±
2
0
±
3
−4
(−12 to 3)
0.241
−3
(−10 to 4)
0.371
−4
(−11 to 3)
0.252
−5
(−16 to 5)
0.283
MI3)
−5
±
4
2
±
4
7
( 2 to 12)
0.198
6
( 0 to 10)
0.250
7
(−4 to 17)
0.196
7
(−6 to 18)
0.223
HDL(mg/dl)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−1
±
1
1
±
1
−0
(−4 to 3)
0.823
−0
(−4 to 3)
0.863
0
(−3 to 4)
0.861
2
(−3 to 8)
0.393
CDS2)
1
±
2
2
±
2
−1
(−6 to 4)
0.745
−1
(−6 to 4)
0.701
0
(−5 to 5)
0.994
2
(−3 to 8)
0.393
MI3) $
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Triglycerides(mg/dl)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LOCF1)
−3
±
8
−5
±
9
2
(−23 to 26)
0.894
4
(−20 to 28)
0.748
2
(−22 to 27)
0.239
7
(−28 to 43)
0.667
CDS2)
−7
±
8
−5
±
9
−3
(−29 to 24)
0.833
4
(−27 to 25)
0.951
−5
(−31 to 22)
0.708
−1
(−38 to 36)
0.953
MI3) $                                    

SE: standard error, 95%CI: 95% confidence interval, degree of freedom = 18.

# Value of HbA1C is JDS15.

1) LOCF: last observation carried forward (IG: n = 100, CG: n = 93).

2) CDS: complete data set. (IG: n = 84), CG: n = 70).

3) MI: Multiple imputation with all analysed variables (number of imputations = 200) (IG: n = 100, CG: n = 93).

Model 1: crude.

Model 2: mixed model adjusted for baseline.

Model 3: mixed model adjusted for baseline, gender, age and BMI.

Model 4: mixed model adjusted for baseline, gender, age, BMI, smoking status, exercise status, change of exercise level, family history of type 2 diabetes, and complication.

$ The MI models did not converge.